Online inquiry

IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15521MR)

This product GTTS-WQ15521MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TGM2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001323316.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7052
UniProt ID P21980
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15521MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15964MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ11752MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ8436MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ15482MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ255MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ11339MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ3018MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ12298MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MSB-0010718C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW